Year: 2025

STOCKHOLM, Sweden, December 22, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company SVF Vaccines has signed a non-binding letter of intent (LOI) with Novakand Pharma AB (“Novakand”) regarding a reverse takeover. Subject to the parties entering into a final agreement and the transaction being approved at Novakand’s extraordinary general meeting, the transaction would result in SVF Vaccines being listed on Nasdaq First North Premier. Through the proposed reverse takeover and an accompanying financing plan, SVF Vaccines aims to accelerate the development of the company’s innovative therapeutic and prophylactic vaccines based on a patented technology originating from Karolinska Institutet. Upon completion of the reverse takeover, SVF Vaccines´ shareholders are expected to hold approximately 67% of...

THEON concludes a transformative 2025 Materially broadened and enhanced strategic platform, total backlog and options of c.€2.4 bn, secured supply chain, and high confidence in (unchanged) profitability guidance Bloomberg (THEON:NA) / Reuters (THEON.AS)22 December 2025 – Theon International Plc (THEON) today provides a review of its strategic, operational and financial progress during 2025, with the key highlights provided below. THEON is also reintroducing profit guidance for FY 2025 and FY 2026 following the successful completion of its Rights Issue (as previously legally constrained to do so) and announces the financial calendar for FY 2026. Importantly, profit guidance remains unchanged at market-leading Adj. EBIT margin of mid-twenties. THEON will announce record revenue and profit for FY 2025 and is entering 2026 with a significantly...

Sampo plc, stock exchange release, 22 December 2025 at 8:30 am EET Sampo plc’s share buybacks 19 December 2025 On 19 December 2025, Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI4000552500) as follows:                Sampo plc’s share buybacks Aggregated daily volume (in number of shares) Daily weighted average price of the purchased shares* Market (MIC Code)  6,513 10.24 AQEU    109,342 10.25 CEUX  40,506 10.24 TQEX  99,300 10.25 XHELTOTAL 255,661 10.25  * rounded to two decimals                      On 5 November 2025, Sampo announced a share buyback programme of up to a maximum of EUR 150 million in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052. The programme, which started on 6 November...

Bigbank AS kinnitas panga 2026. majandusaasta finantskalendri. 2026. aastal plaanib Bigbank avalikustada informatsiooni järgnevatel aegadel:19.02.2026 2025. aasta IV kvartali ja 2025. aasta auditeerimata tulemused25.02.2026 Jaanuari tulemused27.02.2026 2025. aasta auditeeritud aastaaruanne 12.03.2026 Veebruari tulemused23.04.2026 I kvartali vahearuanne  14.05.2026 Aprilli tulemused 11.06.2026 Mai tulemused23.07.2026 II kvartali vahearuanne13.08.2026 Juuli tulemused10.09.2026 Augusti tulemused22.10.2026 III kvartali vahearuanne12.11.2026 Oktoobri tulemused10.12.2026 Novembri tulemusedRohkem kui 30-aastase tegevusajalooga Bigbank AS (www.bigbank.ee) on Eesti kapitalile kuuluv kommertspank. 30.11.2025 seisuga oli panga bilansimaht kokku 3,2 miljardit eurot ning omakapital 298 miljonit eurot. Üheksas...

Ipsen gains exclusive global rights, outside of Greater China, for development, manufacturing and commercialization of SIM0613, a LRRC15-targeting antibody-drug conjugate SIM0613 is optimally designed for superior tumor penetration with robust preclinical efficacy data Program expected to enter Phase I clinical development in H2 2026 Simcere Zaiming is eligible to receive up to $1.06B in total paymentsPARIS, FRANCE; 22 DECEMBER 2025 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today an exclusive licensing agreement for global rights outside of Greater China, for SIM0613, an antibody-drug conjugate (ADC) with best-in-class potential. Targeting the LRRC15 protein, SIM0613 is designed for enhanced tumor penetration and differentiated anti-tumor activity in solid tumors with the highest unmet needs. “Today’s announcement underscores...

Lunsumio VELO reduces administration time from 2-4 hours to approximately one minute Availability of Lunsumio VELO allows treatment aligned to people’s clinical needs and personal preferences Approval supported by data demonstrating compelling complete response rate in third-line or later follicular lymphoma, which typically becomes harder to treat after each relapse1,2Basel, 22 December 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved CD20xCD3 bispecific Lunsumio VELO™ (mosunetuzumab), as a subcutaneous (SC) formulation, for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) after two or more lines of systemic therapy, based on results from the phase I/II GO29781 study.1 Based on the study results, Lunsumio VELO...

(Bergen, 22 December 2025) Mowi ASA enters into a strategic and industrial partnership agreement with Skretting/Nutreco where Mowi produces feed based on Skretting’s feed formulation making Mowi an even better salmon farming company. Key highlights:Strategic partnership to deliver more than NOK 650 million (EUR 55 million) in annualised net cost savings through improvements in feed formulation and recipes, procurement and logistics. Mowi Feed with its two state-of-the-art factories to be retained as-is providing an expected EBITDA contribution in 2026E of NOK 825 million (EUR 70 million), and to capitalise on further tightening of the feed market in the coming years. Total EBITDA contribution of feed partnership with Skretting and retained Mowi Feed business unit of more than NOK 1,475 million (EUR 125 million). Total earnings of NOK...

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Clariant, a sustainability-focused specialty chemical company, today announced that the company received two claims for damages against four companies, including Clariant, from MOL Petrolkémia Zrt. and Slovnaft a.s. (MOL Group), Hungary, and Braskem S.A., Brazil, with the court of Munich, Germany. The claims allege damages totaling to around EUR 548 million and EUR 402 million respectively, in relation to infringement of competition law on the ethylene purchasing market which was sanctioned by the European Commission in July 2020. Clariant firmly rejects the allegations and will adamantly defend its position in the proceedings. Clariant has substantiated economic evidence that the conduct of the parties did not produce any effect on the market.      CORPORATE MEDIA RELATIONS   Jochen DubielPhone...

The share repurchase programme runs as from 26 February 2025 and up to and including 30 January 2026 at the latest. In this period, Jyske Bank will acquire shares with a value of up to DKK 2.25 billion, cf. Corporate Announcement No. 3/2025 of 26 February 2025. The share repurchase programme is initiated and structured in compliance with the EU Commission Regulation No. 596/2014 of 16 April 2014, the so-called “Market Abuse Regulation”, and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (together with the Market Abuse Regulation, the “Safe Harbour Rules”). The following transactions have been made under the program:  Number of shares Average purchase price (DKK) Transaction value (DKK)Accumulated, previous announcement 2,911,046 651.22 1,895,738,87415 December 2025 15,000 830.06 12,450,90916...

TORONTO, Dec. 21, 2025 (GLOBE NEWSWIRE) — Allied Gold Corporation (TSX: AAUC, NYSE: AAUC) (“Allied” or the “Company”) is pleased to announce that it has commenced operations and has begun processing ore through the fresh ore comminution circuit installed pursuant to the Phase 1 expansion at Sadiola, marking a significant milestone in the transformational growth strategy for this long-life asset. The Phase 1 expansion is aimed at increasing production, reducing costs and materially increasing cash flows through a phased expansion approach. As previously discussed, with the start of operations of the new fresh ore comminution circuit, Sadiola will be able to increase the proportion of the more abundant fresh ore in the feed from approximately twenty percent up to sixty percent at an expected throughput of 5.7Mt per annum, materially...